https://doi.org/10.55788/f55b16b0
Approximately a quarter of patients with psoriasis will develop inflammatory or PsA. A recent retrospective cohort study using a claims database reported that patients receiving IL-12/23 or IL-23 inhibitors were significantly less likely to develop PsA relative to other classes of biologics [1]. “This will be a talk about a likely new frontier of treating patients with psoriasis getting at the question: Does treatment for psoriasis potentially forestall the development of PsA in patients that don´t have psoriatic arthritis?” explained Prof. Bruce Strober (Yale University School of Medicine, CT, USA) [2]. The objective of the study was to assess whether the risk of inflammatory arthritis or PsA gets delayed according to the type of biologic therapy patients are receiving. The participants in this analysis were enrolled in the Optum Clinformatics Data Mart (CDM) database between January 2014 and December 2022 with 2 ICD-9/ICD-10 diagnosis codes for psoriasis.
Biologic-naïve participants were assigned to 4 cohorts based on the biologics they received first (i.e. IL-23, IL-17, IL12/23, or TNF inhibitors). Participants were followed for up to 3 years, until inflammatory arthritis developed (identified by ICD-9/ICD-10 codes), until participants switched or discontinued their biologics, or were lost to follow-up, whichever occurred first.
The analysis included 7,345 biologic-naïve participants: 2,712 were treated with an IL-23 blocker, 1,078 with an IL-12/23 blocker, 811 with an IL-17 blocker, and 2,744 were in the TNF cohort. Participants receiving an IL-23 blocker for psoriasis had numerically lower incidence rates of inflammatory arthritis and PsA.
When compared with participants receiving IL-23 inhibitors, participants receiving IL-17 (HR 1.44; P=0.0295) or TNF inhibitors (HR 1.9; P<0.0001) were significantly more likely to develop inflammatory arthritis. For the development of PsA, a significant difference was only seen compared with TNF inhibitors (HR 2.05; P<0.001).
However, Prof. Strober emphasised that bias is a potential limitation of this study as healthcare professionals may have preferentially prescribed IL-23 blockers to participants with early markers of PsA. Therefore, the current results should be backed by additional studies regarding the impact of biologics on the future risk of arthritis.
- Singla S, et al. Lancet Rheumatol. 2023;5(4):E170–171.
- Strober B. Risk of developing inflammatory arthritis in psoriasis patients initiating treatment with biologics: A population-based analysis. FC08.8, EADV Congress 2023, 11–14 October, Berlin, Germany.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis Next Article
Drug survival of guselkumab and risankizumab seems superior to other biologics »
« First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis Next Article
Drug survival of guselkumab and risankizumab seems superior to other biologics »
Table of Contents: EADV 2023
Featured articles
Tapinarof on course to become a new topical treatment in AD
AD and Eczema in 2023
Tapinarof on course to become a new topical treatment in AD
Upadacitinib provides sustained skin clearance in adolescents and adults with AD
Sustained deep clinical and itch responses with novel IL-13 inhibitor
IL-13 inhibitor shows potential in atopic dermatitis
Encouraging results for amlitelimab in atopic dermatitis
Chronic hand eczema: patients share similar molecular signatures regardless of AD status
Severe hand eczema: dupilumab could be a future treatment
Psoriasis News
Dual IL-17 blockade yields efficacy on joints and skin
High-dose subcutaneous spesolimab prevents GPP flares up to week 48
Drug survival of guselkumab and risankizumab seems superior to other biologics
IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis
First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis
Hidradenitis Suppurativa: End of the Diagnostic and Therapeutic Draught
Skin tape stripping allows a novel precision medicine approach in HS
Nanobodies: A novel way to treat HS
Anti-IL17 blockade leads to maintained pain reduction in patients with HS
Vitiligo: Novel Treatment Options
JAK1 inhibition: a promising forthcoming treatment option in vitiligo
Vitiligo: Continuation of topical ruxolitinib successful in many initial non-responders
Alopecia Areata: Novel Developments
JAK3/TEC inhibition achieves clinically meaningful responses in AA
Alopecia areata: remarkable regrowth rates with deuruxolitinib
Botanical drug solution improves hair regrowth in children and adolescents with AA
What’s New in Other Disease Entities
Nemolizumab shows high success rates in prurigo nodularis
Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU
Innovative wound gel reduces frequency of painful dressing changes in epidermolysis bullosa
Best of the Posters
Women with psoriasis face increased adverse effects with systemic therapy
Improved AI tool shows high sensitivity rates in skin cancer detection
Dermoscopy training combined with AI significantly improves skin cancer detection
Related Articles
November 19, 2021
IFN-γ signature predicts response to immunotherapy

© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com